Literature DB >> 21242014

Type 2 diabetes risk in persons with dysglycemia: the Framingham Offspring Study.

Peter W F Wilson1, Ralph B D'Agostino, Caroline S Fox, Lisa M Sullivan, James B Meigs.   

Abstract

AIMS: Detection of risk of type 2 diabetes mellitus (T2DM) among adults with dysglycemia.
METHODS: We used a nested case-cohort prospective design to estimate risk of new diabetes (diabetes treatment or FPG ≥7.0 mmol/L) among 1004 Framingham Heart Study Offspring with baseline dysglycemia [fasting plasma glucose (FPG) 5.4-6.9 mmol/L and/or 2-h post glucose load level 7.8-11.0 mmol/L]. Using clinical characteristics previously shown to predict incident T2DM, we used logistic regression to estimate odds ratios (OR), p-values for predictors, and assessment of model discrimination.
RESULTS: At the end of 7 years follow-up there were 118 incident T2DM cases. In a model that included age, sex, elevated blood pressure or blood pressure treatment, lipid-lowering treatment and elevated triglycerides, we found the following additional characteristics to be independently associated with new T2DM: parental history of diabetes (OR 2.28, p=0.004); excess adiposity (BMI ≥30 kg/m(2) or waist circumference ≥101.6 cm) (OR 2.04, p=0.0005), and low HDL-C [<1.0 (men) or <1.3 mmol/L (women)] (OR 2.77, p<0.0001). The multivariable C-statistic for this model was 0.701, and with glycemic category information included, c=0.751.
CONCLUSIONS: The key non-glycemic traits that predicted later T2DM in adults with dysglycemia were parental history of diabetes, excess adiposity and low HDL-C.
Copyright © 2010. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21242014      PMCID: PMC3079064          DOI: 10.1016/j.diabres.2010.12.024

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  14 in total

1.  Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study.

Authors:  J B Meigs; R B D'Agostino; P W Wilson; L A Cupples; D M Nathan; D E Singer
Journal:  Diabetes       Date:  1997-10       Impact factor: 9.461

2.  Risk for diabetes mellitus in middle-aged Caucasian male participants of the PROCAM study: implications for the definition of impaired fasting glucose by the American Diabetes Association. Prospective Cardiovascular Münster.

Authors:  A von Eckardstein; H Schulte; G Assmann
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

3.  Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study.

Authors:  Maria Inês Schmidt; Bruce B Duncan; Heejung Bang; James S Pankow; Christie M Ballantyne; Sherita H Golden; Aaron R Folsom; Lloyd E Chambless
Journal:  Diabetes Care       Date:  2005-08       Impact factor: 19.112

Review 4.  The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk.

Authors:  Henry N Ginsberg; Anton F H Stalenhoef
Journal:  J Cardiovasc Risk       Date:  2003-04

5.  Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test?

Authors:  Michael P Stern; Ken Williams; Steven M Haffner
Journal:  Ann Intern Med       Date:  2002-04-16       Impact factor: 25.391

6.  Predicting the development of diabetes in older adults: the derivation and validation of a prediction rule.

Authors:  Alka M Kanaya; Christina L Wassel Fyr; Nathalie de Rekeneire; Ronald I Shorr; Ann V Schwartz; Bret H Goodpaster; Anne B Newman; Tamara Harris; Elizabeth Barrett-Connor
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

7.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.

Authors:  J Tuomilehto; J Lindström; J G Eriksson; T T Valle; H Hämäläinen; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Laakso; A Louheranta; M Rastas; V Salminen; M Uusitupa
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

8.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

9.  Comparison of a clinical model, the oral glucose tolerance test, and fasting glucose for prediction of type 2 diabetes risk in Japanese Americans.

Authors:  Marguerite J McNeely; Edward J Boyko; Donna L Leonetti; Steven E Kahn; Wilfred Y Fujimoto
Journal:  Diabetes Care       Date:  2003-03       Impact factor: 19.112

10.  Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study.

Authors:  Anthony J G Hanley; Ken Williams; Clicerio Gonzalez; Ralph B D'Agostino; Lynne E Wagenknecht; Michael P Stern; Steven M Haffner
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

View more
  3 in total

1.  Cholesterol-induced hepatic inflammation does not underlie the predisposition to insulin resistance in dyslipidemic female LDL receptor knockout mice.

Authors:  Nanda Gruben; Anouk Funke; Niels J Kloosterhuis; Marijke Schreurs; Fareeba Sheedfar; Rick Havinga; Sander M Houten; Ronit Shiri-Sverdlov; Bart van de Sluis; Jan Albert Kuivenhoven; Debby P Y Koonen; Marten H Hofker
Journal:  J Diabetes Res       Date:  2015-02-28       Impact factor: 4.011

2.  Ultra-performance liquid chromatography-mass spectrometry-based metabolomics reveals Huangqiliuyi decoction attenuates abnormal metabolism as a novel therapeutic opportunity for type 2 diabetes.

Authors:  Jiao Xu; Zhe-Hui Jiang; Xiu-Bo Liu; Yan Ma; Wei Ma; Ling Ma
Journal:  RSC Adv       Date:  2019-12-02       Impact factor: 4.036

3.  Do non-glycaemic markers add value to plasma glucose and hemoglobin a1c in predicting diabetes? Yuport health checkup center study.

Authors:  Saori Kashima; Kazuo Inoue; Masatoshi Matsumoto; Kimihiko Akimoto
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.